We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App





Novel Study on Performance of Coronavirus Tests in Children Presented at 2021 AACC Annual Scientific Meeting

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Illustration
Illustration

The findings of a novel study on the performance of coronavirus tests in children were presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

A team of researchers from the University of Toronto (Toronto, Canada) set out to investigate the accuracy of coronavirus antigen and antibody tests in a pediatric population. The aim was to overcome the problem of the majority of FDA-authorized coronavirus tests being validated primarily using data from adults, meaning that these tests might not be as accurate in pediatric patients, thus posing a key challenge with COVID-19 care.

The researchers tested 140 asymptomatic children and adolescents (ages 5 to 18) with a coronavirus antigen test and an antibody test. From this, they found that the tests’ performance in pediatric individuals was on par with the tests’ performance in adults. All of the antigen test results were negative, which was in keeping with the fact that all study participants were asymptomatic. Furthermore, all of the study participants (3%) who had positive antibody test results had also previously tested positive for the coronavirus in the past.

“A lot of the literature focuses on adults right now, and our study has been one of the few to go into the community and see the performance of these tests in asymptomatic school children and adolescents,” said Mary Kathryn Bohn, a PhD candidate at the University of Toronto, who led the research. “These types of studies will be really important, especially as the school year starts.”

Related Links:
University of Toronto 

Gold Supplier
TBI Blood Test
i-STAT TBI Plasma Test
New
Chemiluminescence Analyzer
DZ-Lite 3000 Plus
New
Gold Supplier
Automatic Biochemistry Analyzer
Biossays C8
New
SARS-CoV-2 IgG Antibodies Anti-S1 Assay
iRapid SARS-CoV-2 Quant "Neutralizing" Ab

Print article
AACC

Channels

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.